Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial

Trial Profile

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms SCALE; SCALE-Sleep Apnoea
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Apr 2016 Results (pooled analysis of this and other four trials, n = 5338) assessing neuropsychiatric Safety Profile presented at The 98th Annual Meeting of the Endocrine Society.
    • 08 May 2015 According to the Novo Nordisk media release, further data from this and other three SCALE trials (see profile 193291, 193353 and 38848) expected to be presented and published in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top